Generative artificial intelligence empowers digital twins in drug discovery and clinical trials
Helmholtz Zentrum München · Roche Pharma AG (Germany) · +6 more institutions
Abstract
INTRODUCTION: The concept of Digital Twins (DTs) translated to drug development and clinical trials describes virtual representations of systems of various complexities, ranging from individual cells to entire humans, and enables in silico simulations and experiments. DTs increase the efficiency of drug discovery and development by digitalizing processes associated with high economic, ethical, or social burden. The impact is multifaceted: DT models sharpen disease understanding, support biomarker discovery and accelerate drug development, thus advancing precision medicine. One way to realize DTs is by generative artificial intelligence (AI), a cutting-edge technology that enables the creation of novel,…
Citation impact
- FWCI
- 37.17
- Percentile
- 100%
- References
- 58
Authors
5- MBMaria Bordukova
Helmholtz Zentrum München, Roche Pharma AG (Germany), Ludwig-Maximilians-Universität München
- NMNikita Makarov
Helmholtz Zentrum München, Roche Pharma AG (Germany), Ludwig-Maximilians-Universität München
- RRRaul Rodriguez‐Esteban
Roche (Switzerland)
- FSFabian SchmichCorresponding
Roche Pharma AG (Germany)
- MPMichael P. MendenCorresponding
The University of Melbourne, Helmholtz Zentrum München, Deutsches Diabetes-Zentrum e.V., German Center for Diabetes Research, Heinrich Heine University Düsseldorf, Ludwig-Maximilians-Universität München
Topics & keywords
- Generative grammar
- Drug discovery
- Computer science
- Precision medicine
- Virtual screening
- Data science
- Artificial intelligence
- Drug development